Список литературы

1. Alaggio R. et al. The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms//Leuk. 2022 367. Nature Publishing Group, 2022. Vol. 36, N 7. P. 1720 - 1748.

2. de Larrea C. et al. Primary plasma cell leukemia: consensus definition by the International Myeloma Working Group according to peripheral blood plasma cell percentage//Blood Cancer J. Nature Publishing Group, 2021. Vol. 11, N 12.

3. Jung S.-H., Lee J.-J. Update on primary plasma cell leukemia. 2022.

4. Tveden Gundesen M. et al. Plasma Cell Leukemia: Definition, Presentation, and Treatment. 1912.

5. Van De Donk N.W.C.J. et al. How I treat plasma cell leukemia. 2012.

6. Durie B.G.M., Salmon S.E. A clinical staging system for multiple myeloma correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival//Cancer. 1975. Vol. 36, N 3. P. 842 - 854.

7. Greipp P.R. et al. International staging system for multiple myeloma//J. Clin. Oncol. 2005. Vol. 23, N 15. P. 3412 - 3420.

8. Palumbo A. et al. Revised international staging system for multiple myeloma: A report from international myeloma working group//J. Clin. Oncol. 2015.

9. D'agostino M. et al. Second Revision of the International Staging System (R2-ISS) for Overall Survival in Multiple Myeloma: A European Myeloma Network (EMN) Report Within the HARMONY Project//J. Clin. Oncol. Lippincott Williams and Wilkins, 2022. Vol. 364.

10. Papadhimitriou S.I. et al. The Cytogenetic Profile of Primary and Secondary Plasma Cell Leukemia: Etiopathogenetic Perspectives, Prognostic Impact and Clinical Relevance to Newly Diagnosed Multiple Myeloma with Differential Circulating Clonal Plasma Cells//Biomedicines. Biomedicines, 2022. Vol. 10, N 2.

11. Бессмельцев С.С. Множественная миелома//Вестник гематологии. 2014. Vol. 10, N 3. P. 6 - 39.

12. Rajkumar S.V. et al. International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma//Lancet Oncol. Elsevier Ltd, 2014. Vol. 15, N 12. P. e538 - e548.

13. Musto P. et al. An update on biology, diagnosis and treatment of primary plasma cell leukemia//Expert Rev. Hematol. Taylor & Francis, 2019. Vol. 12, N 4. P. 245 - 253.

14. Visram A. et al. Practical management and assessment of primary plasma cell leukemia in the novel agent era//Cancer Treat. Res. Commun. Elsevier, 2021. Vol. 28. P. 100414.

15. Chaulagain C.P. et al. Management of Primary Plasma Cell Leukemia Remains Challenging Even in the Era of Novel Agents//Clin. Med. Insights Blood Disord. SAGE Publications, 2021. Vol. 14.

16. Kyle R.A., Rajkumar S. V. Criteria for diagnosis, staging, risk stratification and response assessment of multiple myeloma.//Leukemia. 2009. Vol. 23, N 1. P. 3 - 9.

17. Moreau P. et al. Multiple myeloma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up//Ann. Oncol. 2017. Vol. 28, N suppl_4. P. iv52 - iv61.

18. Менделеева Л.П., Вотякова О.М., Рехтина И.Г. Множественная миелома. Российские клинические рекомендации по диагностике и лечению злокачественных лимфопролиферативных заболеваний./ed. Поддубной И.В., Савченко В.Г. Москва, 2018. 213 - 241 p.

19. Gavriatopoulou M. et al. European myeloma network recommendations on diagnosis and management of patients with rare plasma cell dyscrasias//Leukemia. 2018. Vol. 32. P. 1883 - 1898.

20. Coppola A. et al. Bleeding and thrombosis in multiple myeloma and related plasma cell disorders.//Semin. Thromb. Hemost. 2011. Vol. 37, N 8. P. 929 - 945.

21. Tripathy S. The role of serum protein electrophoresis in the detection of multiple myeloma: An experience of a corporate hospital//J. Clin. Diagnostic Res. 2012. Vol. 6, N 9. P. 1458 - 1461.

22. Misra A. et al. Old but Still Relevant: High Resolution Electrophoresis and Immunofixation in Multiple Myeloma//Indian Journal of Hematology and Blood Transfusion. Springer India, 2016. Vol. 32, N 1. P. 10 - 17.

23. Любимова Н.В. et al. Свободные легкие цепи иммуноглобулинов в диагностике и прогнозе множественной миеломы.//Альманах клинической медицины. 2017. Vol. 45, N 2. P. 102 - 108.

24. Julie D. et al. Comparison of Bone marrow Aspirate and Bone marrow Biopsy in the workup of Patients with Multiple Myeloma//Clin. Lymphoma Myeloma Leuk. Elsevier BV, 2015. Vol. 15. P. e117.

25. van de Donk N.W.C.J. et al. How I treat plasma cell leukemia//Blood. 2012. Vol. 120, N 12. P. 2376 - 2389.

26. Pianko M.J. et al. Whole-body low-dose computed tomography and advanced imaging techniques for multiple myeloma bone disease//Clinical Cancer Research. American Association for Cancer Research Inc., 2014. Vol. 20, N 23. P. 5888 - 5897.

27. Cavo M. et al. Role of 18F-FDG PET/CT in the diagnosis and management of multiple myeloma and other plasma cell disorders: a consensus statement by the International Myeloma Working Group.//Lancet. Oncol. 2017. Vol. 18, N 4. P. e206 - e217.

28. Katodritou E. et al. Treatment with bortezomib-based regimens improves overall response and predicts for survival in patients with primary or secondary plasma cell leukemia: Analysis of the Greek myeloma study group//Am. J. Hematol. Am J Hematol, 2014. Vol. 89, N 2. P. 145 - 150.

29. Royer B. et al. Bortezomib, Doxorubicin, Cyclophosphamide, Dexamethasone Induction Followed by Stem Cell Transplantation for Primary Plasma Cell Leukemia: A Prospective Phase II Study of the Intergroupe Francophone du //J. Clin. Oncol. J Clin Oncol, 2016. Vol. 34, N 18. P. 2125 - 2132.

30. D'Arena G. et al. Frontline chemotherapy with bortezomib-containing combinations improves response rate and survival in primary plasma cell leukemia: a retrospective study from GIMEMA Multiple Myeloma Working Party//Ann. Oncol. Off. J. Eur. Soc. Med. Oncol. Ann Oncol, 2012. Vol. 23, N 6. P. 1499 - 1502.

31. Katodritou E. et al. Improved survival of patients with primary plasma cell leukemia with VRd or daratumumab-based quadruplets: A multicenter study by the Greek myeloma study group//Am. J. Hematol. John Wiley and Sons Inc, 2023. Vol. 98, N 5. P. 730 - 738.

32. Royer B. et al. Long Term Follow-up of Hematopoietic Stem Cell Transplantation (HSCT) for Primary Plasma Cell Leukemia (pPCL): Final Results of a Prospective Study of IFM Group//Blood. American Society of Hematology, 2016. Vol. 128, N 22. P. 4612 - 4612.

33. Usmani S.Z. et al. Bortezomib, lenalidomide, and dexamethasone with or without elotuzumab in patients with untreated, high-risk multiple myeloma (SWOG-1211): primary analysis of a randomised, phase 2 trial//Lancet. Haematol. NIH Public Access, 2021. Vol. 8, N 1. P. e45.

34. Telek B. et al. Effective PAD (bortezomib, doxorubicine, dexamethasone) treatment of a patient with plasma cell leukaemia developed after autologous stem cell transplantation//Orv. Hetil. , 2008. Vol. 149, N 41. P. 1957 - 1959.

35. Musto P. et al. Lenalidomide and low-dose dexamethasone for newly diagnosed primary plasma cell leukemia//Leuk. 2014 281. Nature Publishing Group, 2013. Vol. 28, N 1. P. 222 - 225.

36. van de Donk N.W.C.J. et al. Treatment of primary plasma cell leukaemia with carfilzomib and lenalidomide-based therapy (EMN12/HOVON-129): final analysis of a non-randomised, multicentre, phase 2 study//Lancet Oncol. Elsevier Ltd, 2023. Vol. 24, N 10. P. 1119 - 1133.

37. Kaiser M.F. et al. Daratumumab, Cyclophosphamide, Bortezomib, Lenalidomide, and Dexamethasone as Induction and Extended Consolidation Improves Outcome in Ultra-High-Risk Multiple Myeloma//J. Clin. Oncol. Lippincott Williams and Wilkins, 2023. Vol. 41, N 23. P. 3945 - 3955.

38. Lawless S. et al. Comparison of autologous and allogeneic hematopoietic cell transplantation strategies in patients with primary plasma cell leukemia, with dynamic prediction modeling//Haematologica. Ferrata Storti Foundation, 2023. Vol. 108, N 4. P. 1105 - 1114.

39. Costa L.J. et al. Minimal residual disease response-adapted therapy in newly diagnosed multiple myeloma (MASTER): final report of the multicentre, single-arm, phase 2 trial//Lancet Haematol. Elsevier, 2023. Vol. 10, N 11. P. e890 - e901.

40. Derman B.A. et al. Final analysis of a phase II trial of daratumumab, carfilzomib, lenalidomide, and dexamethasone in newly diagnosed multiple myeloma without transplant//Blood Cancer J. Nature Publishing Group, 2024. Vol. 14, N 1.

41. Leypoldt L.B. et al. Isatuximab, carfilzomib, lenalidomide, and dexamethasone (Isa-KRd) in front-line treatment of high-risk multiple myeloma: interim analysis of the GMMG-CONCEPT trial//Leukemia. Leukemia, 2022. Vol. 36, N 3. P. 885 - 888.

42. Leypoldt L.B. et al. Isatuximab, Carfilzomib, Lenalidomide, and Dexamethasone for the Treatment of High-Risk Newly Diagnosed Multiple Myeloma//J. Clin. Oncol. J Clin Oncol, 2024. Vol. 42, N 1. P. 26 - 37.

43. O'Donnell E. et al. Isatuximab, carfilzomib, lenalidomide, and dexamethasone in patients with newly diagnosed, transplantation-eligible multiple myeloma (SKylaRk): a single-arm, phase 2 trial//Lancet. Haematol. Lancet Haematol, 2024. Vol. 11, N 6. P. e415 - e424.

44. Mahindra A. et al. Hematopoietic Cell Transplantation for Primary Plasma Cell Leukemia: Results from the Center for International Blood and Marrow Transplant Research//Leukemia. NIH Public Access, 2012. Vol. 26, N 5. P. 1091.

45. Dhakal B. et al. Hematopoietic Cell Transplantation Utilization and Outcomes for Primary Plasma Cell Leukemia in the Current Era//Leukemia. NIH Public Access, 2020. Vol. 34, N 12. P. 3338.

46. Gowda L. et al. Primary Plasma Cell Leukemia: Autologous Stem Cell Transplant in an Era of Novel Induction Drugs//Bone Marrow Transplant. NIH Public Access, 2019. Vol. 54, N 7. P. 1089.

47. Lemieux C. et al. Outcomes with Autologous or Allogeneic Stem Cell Transplantation in Patients with Plasma Cell Leukemia in the Era of Novel Agents//Biol. Blood Marrow Transplant. NIH Public Access, 2020. Vol. 26, N 12. P. e328.

48. Mahindra A. et al. Hematopoietic Cell Transplantation for Primary Plasma Cell Leukemia: Results from the Center for International Blood and Marrow Transplant Research HHS Public Access//Leukemia. 2012. Vol. 26, N 5. P. 1091 - 1097.

49. Dhakal B. et al. Hematopoietic Cell Transplantation Utilization and Outcomes for Primary Plasma Cell Leukemia in the Current Era HHS Public Access//Leukemia. 2020. Vol. 34, N 12. P. 3338 - 3347.

50. Tveden Gundesen M. et al. Plasma Cell Leukemia: Definition, Presentation, and Treatment. 1912.

51. Drake M. et al. Primary plasma cell leukemia and autologous stem cell transplantation on behalf of the European Group for Blood and Marrow Transplantation and the European Leukemia Net//Haematologica. 2010. Vol. 95. P. 804 - 809.

52. Larocca A. et al. Patient-centered practice in elderly myeloma patients: an overview and consensus from the European Myeloma Network (EMN)//Leukemia. 2018. Vol. 32. P. 1697 - 1712.

53. Dampmann M. et al. Single-Center Experience of Patients with Plasma Cell Leukemia in the Era of New Therapeutics//Acta Haematol. S. Karger AG, 2024. P. 1 - 8.

54. Nakaya A. et al. Retrospective analysis of primary plasma cell leukemia in Kansai Myeloma Forum registry//Leuk. Res. Reports. Elsevier, 2018. Vol. 10. P. 7.

55. Tang A.S.O. et al. Plasma Cell Leukemia with Successful Upfront Venetoclax in Combination with Allogeneic Transplantation//Am. J. Case Rep. International Scientific Information, Inc., 2023. Vol. 24. P. e938868 - 1.

56. Абузарова Г.Р. et al. Обезболивание взрослых и детей при оказании медицинской помощи. Методические рекомендации. ФГБОУ ВО РНИМУ им. Н.И. Пирогова Минздрава России., 2016. 94 p.

57. Соловьев М.В., Соловьева М.В., Менделеева Л.П. Сопроводительная терапия при множественной миеломе: практические рекомендации//Клиническая онкогематология. 2023. Vol. 16, N 4. P. 426 - 448.

58. De Larrea C. et al. Plasma cell leukemia: consensus statement on diagnostic requirements, response criteria and treatment recommendations by the International Myeloma Working Group//Leukemia. Leukemia, 2013. Vol. 27, N 4. P. 780 - 791.

59. Paul K.L. Rehabilitation and exercise considerations in hematologic malignancies.//Am. J. Phys. Med. Rehabil. 2011. Vol. 90, N 5 Suppl 1. P. S88 - 94.

60. Attal M. et al. Lenalidomide, Bortezomib, and Dexamethasone with Transplantation for Myeloma//N. Engl. J. Med. New England Journal of Medicine (NEJM/MMS), 2017. Vol. 376, N 14. P. 1311 - 1320.

61. L. et al. Bortezomib, lenalidomide, and dexamethasone as induction therapy prior to autologous transplant in multiple myeloma//Blood. American Society of Hematology, 2019. Vol. 134, N 16. P. 1337 - 1345.

62. Leiba M. et al. Bortezomib-Cyclophosphamide-Dexamethasone (VCD) versus Bortezomib-Thalidomide-Dexamethasone (VTD) - based regimens as induction therapies in newly diagnosed transplant eligible patients with multiple myeloma: A meta-analysis//Br. J. Haematol. Blackwell Publishing Ltd, 2014. Vol. 166, N 5. P. 702 - 710.

63. Popat R. et al. Bortezomib, doxorubicin and dexamethasone (PAD) front-line treatment of multiple myeloma: updated results after long-term follow-up//Br. J. Haematol. John Wiley & Sons, Ltd, 2008. Vol. 141, N 4. P. 512 - 516.

64. Nooka A.K. et al. Bortezomib-containing induction regimens in transplant-eligible myeloma patients//Cancer. 2013. Vol. 119, N 23. P. 4119 - 4128.

65. Oken M.M. et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group//Am. J. Clin. Oncol. 1982. Vol. 5, N 6. P. 649 - 655.